A big jump in preventing problems in refractive surgery for myopia

Fact Sheet

Project Information

**KERASTOP**
Grant agreement ID: 775591

**Funded under**
INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology

**DOI**
10.3030/775591

**Total cost**
€ 71 429,00

**EU contribution**
€ 50 000,00

**Coordinated by**
CORNEA PROJECT SL
Spain

**Start date**
1 June 2017

**End date**
31 August 2017

Objective

The treatment of myopia using the excimer laser technology has been standardized globally. It is the main business for ophthalmologists in private practice. Most of patients undergoing laser refractive surgery achieve a good outcome, but there is a reduced volume of patients that develop a devastating disease, the post-LASIK ectasia. This condition is due to the performance of surgery in eyes with a pathology called keratoconus. It is not completely understood and generates a degradation of
vision, with the potential of leading to extreme conditions requiring corneal transplantation. It is a very traumatic situation for both patients and doctors. Nowadays, keratoconus is only diagnosed when clinical signs are present. Ophthalmologists search for signs in the corneal surface indicating the potential presence of keratoconus and preventing the risk for the development of the disease. This leads to the avoidance of performing surgery in a great volume of patients due to a theoretical risk of ectasia development.

CORNEA PROJECT has two biomarkers directly related to the presence of keratoconus. Based on the use of these biomarkers, KERASTOP will provide a fast in situ diagnostic test, with high levels of sensitivity and specificity (over 90%) that will facilitate the doctor to determine if the pathology is present, even in very initial stages not detected with the current diagnostic tests. KERASTOP will reduce the risks in refractive surgery, will increase the volume of candidates suitable for surgery and will allow the performance of more surgeries with more safety.

CORNEA PROJECT is composed of two foundational partners with more than 15 years of experience in the laser refractive surgery sector worldwide. Likewise, the company has a human team composed of very relevant experts in the area of biotechnology and ophthalmology. In 5 years, the company is expected to have a positive EBITDA of more than 30 million of euros and to have generated more than 90 employments.

**Fields of science**

- medical and health sciences > clinical medicine > ophthalmology
- medical and health sciences > clinical medicine > surgery > surgical procedures
- medical and health sciences > basic medicine > pathology
- medical and health sciences > clinical medicine > transplantation
- natural sciences > physical sciences > optics > laser physics

**Programme(s)**

- H2020-EU.2.1.4. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Biotechnology [MAIN PROGRAMME]
- H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument

**Topic(s)**

- SMEInst-03-2016-2017 - Dedicated support to biotechnology SMEs closing the gap from lab to market
Call for proposal

H2020-SMEInst-2016-2017

See other projects for this call

Sub call

H2020-SMEINST-1-2016-2017

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

CORNEA PROJECT SL

Net EU contribution

€ 50 000,00

Address

Calle anna maria martinez sagi num 28 p
08041 Barcelona
Spain

SME
Yes

Region

Este > Cataluña > Barcelona

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Contact the organisation
Participation in EU R&I programmes
HORIZON collaboration network

Total cost

€ 71 429,00

Last update: 11 August 2022